Patricia Danzon

Is the U.S. Ready for Value-based Pricing of Drugs?

May 18, 2016
Public Policy
North America
mic

The federal government’s move to switch to value-based pricing of drugs for one category of public health plans could potentially have far-reaching effects, say experts.

Why Cuba Stands Tall in Health Care Metrics

Nov 25, 2015
Public Policy
Latin America
mic

Despite the decades-long U.S. trade embargo, Cuba's health care system has thrived, with metrics that are comparable not only with other countries in the same per capita income bracket, but[…]

Technology Increasingly Key to Better Patient Outcomes

Dec 16, 2014
Technology
Global Focus
page

More health care providers choose mobility, wearable sensors and other digital technologies for better patient outcomes.

‘Trying to Recapture the Magic’: The Strategy Behind the Pharma M&A Rush

In the midst of an M&A frenzy in the global pharmaceutical industry, Wharton experts advise companies to keep a watchful eye on runaway valuations and post-merger integration.

Sovaldi: Who’s to Blame for the $1,000 a Day Cure?

The eye-popping price tag for the hepatitis C drug Sovaldi has insurers and patient advocates up in arms. The fault doesn't rest with drugmaker Gilead, Wharton experts say, but with[…]

Faculty Archive

Is the U.S. Ready for Value-based Pricing of Drugs?

Why Cuba Stands Tall in Health Care Metrics

SPONSORED CONTENT

Technology Increasingly Key to Better Patient Outcomes

‘Trying to Recapture the Magic’: The Strategy Behind the Pharma M&A Rush

Sovaldi: Who’s to Blame for the $1,000 a Day Cure?